USP7-Dependent Regulation of TRAF Activation and Signaling by a Viral Interferon Regulatory Factor Homologue.
Gene Deletion
HEK293 Cells
Herpesvirus 8, Human
/ physiology
Humans
Interferon Regulatory Factors
/ genetics
Intracellular Signaling Peptides and Proteins
/ genetics
TNF Receptor-Associated Factor 3
/ genetics
Ubiquitin-Specific Peptidase 7
/ genetics
Viral Proteins
/ genetics
Virus Latency
/ physiology
TRAF3
TRAF6
herpesvirus-associated ubiquitin-specific protease
human herpesvirus 8
latency
replication
tumor necrosis factor receptor-associated factors
ubiquitin-specific protease 7
viral interferon regulatory factor-2
Journal
Journal of virology
ISSN: 1098-5514
Titre abrégé: J Virol
Pays: United States
ID NLM: 0113724
Informations de publication
Date de publication:
06 01 2020
06 01 2020
Historique:
received:
11
09
2019
accepted:
22
10
2019
pubmed:
2
11
2019
medline:
10
6
2020
entrez:
1
11
2019
Statut:
epublish
Résumé
Human herpesvirus 8 (HHV-8) encodes four viral interferon regulatory factors (vIRFs 1 to 4), all of which are expressed during lytic replication and inhibit a variety of antiviral signaling pathways. Viral IRFs 1, 2, and 3 are also expressed during latency in primary effusion lymphoma (PEL) cells, and vIRF-1 and vIRF-3 have been reported to promote PEL cell viability. Viral IRFs 1, 3, and 4 are known to interact with ubiquitin-specific protease 7 (USP7); interactions of vIRF-1 and vIRF-3 with USP7 promote PEL cell viability and regulate productive replication. Here, we report that vIRF-2 also targets USP7, utilizing a PSTS motif matching the USP7 N-terminal domain-binding A/PxxS consensus, but uniquely requires catalytic domain residues for intracellular interaction. In functional and mechanistic analyses, tumor necrosis factor receptor-associated factor (TRAF)-mediated signaling and associated polyubiquitination of TRAFs 3 and 6, specifically, were regulated negatively by USP7 and positively by vIRF-2-USP7 interaction, the latter competing for USP7-TRAF association. Using depletion, depletion-complementation, and targeted mutagenesis approaches, vIRF-2 was determined to promote latent PEL cell viability, likely independently of USP7 interaction, while lytic replication was inhibited by vIRF-2, in part or in whole via USP7 interaction. Together, our data identify a new molecular determinant of USP7 recognition, TRAF3/6-specific targeting by the deubiquitinase, associated activation of these TRAFs by vIRF-2, and activities of vIRF-2 and vIRF-2-USP7 interaction in HHV-8 latent and lytic biology.
Identifiants
pubmed: 31666375
pii: JVI.01553-19
doi: 10.1128/JVI.01553-19
pmc: PMC6955280
pii:
doi:
Substances chimiques
Interferon Regulatory Factors
0
Intracellular Signaling Peptides and Proteins
0
TNF Receptor-Associated Factor 3
0
TRAF3 protein, human
0
Tifab protein, human
0
Viral Proteins
0
viral interferon regulatory factors
0
USP7 protein, human
EC 3.4.19.12
Ubiquitin-Specific Peptidase 7
EC 3.4.19.12
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : NIAID NIH HHS
ID : R01 AI140855
Pays : United States
Organisme : NCI NIH HHS
ID : R21 CA196348
Pays : United States
Informations de copyright
Copyright © 2020 Xiang et al.
Références
Blood. 2009 Apr 2;113(14):3264-75
pubmed: 18952891
J Neurosci. 2005 Feb 23;25(8):2002-9
pubmed: 15728840
J Biol Chem. 2009 Mar 27;284(13):8525-38
pubmed: 19129183
J Virol. 1999 Oct;73(10):8268-78
pubmed: 10482577
J Gen Virol. 2003 Jun;84(Pt 6):1471-83
pubmed: 12771416
PLoS Pathog. 2019 May 6;15(5):e1007743
pubmed: 31059555
J Virol. 2003 Apr;77(7):4205-20
pubmed: 12634378
J Virol. 2009 Jul;83(13):6739-47
pubmed: 19369353
J Virol. 2012 Sep;86(18):9708-20
pubmed: 22740391
EMBO J. 2007 Sep 5;26(17):3910-22
pubmed: 17703191
J Biol Chem. 2016 Mar 18;291(12):6281-91
pubmed: 26786098
PLoS Pathog. 2018 May 10;14(5):e1007058
pubmed: 29746593
J Mol Signal. 2013 Jun 13;8(1):7
pubmed: 23758787
J Hum Virol. 1999 Jan-Feb;2(1):19-32
pubmed: 10200596
J Biol Chem. 2001 Jun 29;276(26):24242-52
pubmed: 11279055
J Virol. 2018 Mar 14;92(7):
pubmed: 29343584
Mol Cell Biol. 2014 Feb;34(3):386-99
pubmed: 24248600
Curr Opin Infect Dis. 2011 Aug;24(4):295-301
pubmed: 21666458
J Biol Chem. 2003 Aug 8;278(32):29987-94
pubmed: 12783858
Methods Mol Biol. 2010;634:421-30
pubmed: 20677001
J Biol Chem. 2009 Aug 28;284(35):23272-85
pubmed: 19553679
EMBO J. 2010 Aug 4;29(15):2553-65
pubmed: 20601937
Biotechniques. 2006 Feb;40(2):191-7
pubmed: 16526409
Oncogene. 2004 Aug 12;23(36):6146-55
pubmed: 15208654
Oncogene. 2001 Feb 15;20(7):800-11
pubmed: 11314014
Nat Struct Mol Biol. 2011 Nov 06;18(12):1336-44
pubmed: 22056774
Int J Cancer. 2015 Jul 15;137(2):251-61
pubmed: 24771491
J Virol. 2007 Aug;81(15):8282-92
pubmed: 17522209
J Virol. 2001 Jul;75(13):6193-8
pubmed: 11390621
Front Microbiol. 2012 Mar 02;3:73
pubmed: 22403576
J Virol. 2001 Mar;75(5):2345-52
pubmed: 11160738
J Interferon Cytokine Res. 2009 Sep;29(9):621-7
pubmed: 19715458
J Virol Methods. 2011 Jun;174(1-2):12-21
pubmed: 21419799
J Virol. 2015 Oct 28;90(1):506-20
pubmed: 26512076
J Virol. 2015 May;89(9):4918-31
pubmed: 25694600
Biochem Biophys Res Commun. 2016 Feb 12;470(3):650-656
pubmed: 26797279
J Virol. 2006 Mar;80(6):3092-7
pubmed: 16501120
J Virol. 2001 Jan;75(1):429-38
pubmed: 11119611
Oncogene. 1997 Oct 16;15(16):1979-85
pubmed: 9365244
J Mol Cell Biol. 2017 Feb 1;9(1):45-52
pubmed: 27927749
Curr Opin HIV AIDS. 2017 Jan;12(1):47-56
pubmed: 27662501
Eur J Cancer. 2001 Jul;37(10):1251-69
pubmed: 11423257
PLoS Biol. 2006 Feb;4(2):e27
pubmed: 16402859
Nat Struct Mol Biol. 2006 Mar;13(3):285-91
pubmed: 16474402
J Virol. 2012 Jun;86(12):6745-57
pubmed: 22514345
Biochem Biophys Res Commun. 2000 Apr 2;270(1):23-7
pubmed: 10733899
FASEB J. 2018 Oct;32(10):5238-5249
pubmed: 29688809
J Virol. 2006 Mar;80(5):2257-66
pubmed: 16474133
Hum Vaccin Immunother. 2014;10(11):3270-85
pubmed: 25625930
J Virol. 2000 Nov;74(21):10187-93
pubmed: 11024147
J Virol. 2017 Oct 27;91(22):
pubmed: 28878084
Biol Chem. 2017 Jul 26;398(8):857-870
pubmed: 28455950
J Virol. 2015 Aug;89(15):7979-90
pubmed: 26018151
J Mol Biol. 2010 Oct 8;402(5):825-37
pubmed: 20713061
PLoS Pathog. 2010 Aug 05;6(8):e1001031
pubmed: 20700448
Genes Dev. 2013 Feb 1;27(3):274-87
pubmed: 23388826
J Virol. 2009 Jan;83(2):722-33
pubmed: 18987143
J Virol. 2013 Sep;87(17):9398-410
pubmed: 23785197
Nature. 2008 Oct 2;455(7213):674-8
pubmed: 18724357
J Mol Biol. 2017 Nov 10;429(22):3395-3408
pubmed: 28591556
J Virol. 1999 Sep;73(9):7334-42
pubmed: 10438822
J Virol. 2001 Aug;75(16):7572-82
pubmed: 11462029
Transl Cancer Res. 2016 Dec;5(6):707-724
pubmed: 28690977
PLoS Pathog. 2012;8(6):e1002748
pubmed: 22685405